Key result
GLP-1 receptor agonists reduce CV death or worsening heart failure ~32% in HFpEF.
Why the study?
Do GLP-1RAs reduce the composite of CV death or worsening HF events in patients with HFpEF?
Meta-Analysis (n=8,788)
Do GLP-1RAs reduce the composite of CV death or worsening HF events in patients with HFpEF?
GLP-1 receptor agonists significantly reduce worsening heart failure events and the composite of CV death or worsening HF in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
Supports GLP-1RA use in obese/diabetic HFpEF to reduce worsening HF; extends prior trial evidence to this population.
BACKGROUND: Heart failure (HF) with mildly reduced or preserved ejection fraction (HFpEF) accounts for over half of cases of HF, with obesity playing a key role. Residual risk remains high despite available therapies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential cardiometabolic benefits, but their role in HFpEF remains unclear. METHODS: A systematic review and meta-analysis of randomized controlled trials evaluating GLP-1RAs in HFpEF were conducted. Studies evaluating GLP-1RA in combination with glucose-dependent insulinotropic polypeptide (GIP) were also included. The analyzed outcomes included cardiovascular (CV) death, worsening HF events and their composite. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled by using a random-effects model. RESULTS: Six randomized controlled trials involving 8788 patients were included. GLP-1RAs significantly reduced the composite outcome of CV death or worsening HF events (HR: 0.68 [0.51-0.89]; P = 0.006, I² = 47%) as well as worsening HF events alone (HR: 0.56 [0.38-0.82]; P = 0.003, I² = 51%). No significant reduction was observed for CV death alone (HR: 0.86 [0.67-1.12]; P = 0.27, I² = 0%). CONCLUSION: GLP-1RAs reduce worsening HF events and the composite of CV death or worsening HF in HFpEF, particularly in patients with obesity or diabetes. These findings support their role as a promising therapy requiring further HFpEF-focused trials.
No takes yet. Share an insight, caveat, or question.
Waqas et al. (2025) conducted a meta-analysis in Heart failure with mildly reduced or preserved ejection fraction (HFpEF) (n=8,788). GLP-1 receptor agonists (GLP-1RAs) was evaluated on Composite outcome of CV death or worsening HF events (HR 0.68, 95% CI 0.51-0.89, p=0.006). GLP-1 receptor agonists reduced the composite of cardiovascular death or worsening heart failure events in patients with HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: